IMV101 treatment

Phase 2Biologic

SSuzhou Immunofoco Biotechnology Co., Ltd

IMV101 treatment is one of 53 biologic programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaRecruiting

Relapsed/refractory Multiple MyelomaRecruiting

LymphomaPhase 2

Recruiting

Relapsed/refractory Multiple MyelomaPhase 1

Recruiting

Competition

Competitive Landscape

370 competitors in Lymphoma

#DrugCompanyPhaseTrials

Zofran

Novartis

Preclinical

2 2

Norvir

AbbVie

Preclinical

1 3

Cabenuva

GSK

Preclinical

1 4

IMV101 treatment

SSuzhou Immunofoco Biotechnology Co., Ltd

Phase 2

1 5

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—8

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Recruiting

Lymphoma

NCT07376642

Q2 2028

Phase 1Recruiting

Relapsed/refractory Multiple Myeloma

NCT07493135

Clinical

Trials by Indication[1]

Lymphoma1 trial

A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Recruiting·SSuzhou Immunofoco Biotechnology Co., Ltd·Phase 1/2·NCT07376642·30 enrolled

Relapsed/Refractory Multiple Myeloma1 trial

A Single-Arm, Open-Label Early-Phase Clinical Study of IMV102 Injection in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting·SSuzhou Immunofoco Biotechnology Co., Ltd·Phase 1·NCT07493135·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for IMV101 treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IMV101 treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IMV101 treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Suzhou Immunofoco Biotechnology Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: SSuzhou Immunofoco Biotechnology Co., Ltd

IMV101 treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2028

Trials by Indication[1]

Lymphoma1 trial

Relapsed/Refractory Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News